Ras

KRAS Inhibitor-14 is a selective inhibitor targeting the KRAS G12C mutation, exhibiting a potent IC50 of 0.249 µM. It effectively inhibits phosphorylated ERK (p-ERK) with IC50 values of 1.12 µM in MIA PaCA-2 cells and >33.3 µM in A549 cells. This compound is valuable for investigating therapeutic strategies in pancreatic, colorectal, and lung cancers.

KRAS G12C inhibitor 29 is a selective inhibitor targeting the KRAS G12C mutation, which plays a critical role in various cancer types. This compound demonstrates significant activity in suppressing tumor growth in KRAS G12C-driven models, making it a valuable tool for cancer research. It is particularly useful for studies focused on understanding KRAS-related signaling pathways and developing targeted therapies.

Neogrifolin is a selective inhibitor of KRAS, which plays a critical role in the signaling pathways associated with cancer cell proliferation and survival. This compound has demonstrated significant anti-cell viability activity against human cancer cell lines, including HeLa (IC50: 24.3 μM), SW480 (IC50: 34.6 μM), and HT29 (IC50: 30.1 μM). Neogrifolin is primarily utilized in research applications aimed at elucidating the role of KRAS in tumorigenesis and investigating potential therapeutic strategies for KRAS-driven malignancies.

NSC1011 is a selective inhibitor of Ras converting enzyme 1 (Rce1), demonstrating an IC50 of 6.9 µM against the human Rce1. This compound disrupts the localization of key Ras proteins, including EGFR-H-Ras, EGFR-N-Ras, and EGFR-K-Ras. NSC1011 is valuable for research on Ras signaling pathways and their implications in cancer biology.

K-Ras-IN-3 is a selective inhibitor of GDP-bound K-Ras G12V, exhibiting an IC50 value of 0.371 nM. This compound demonstrates significant potential for cancer research, particularly in the study of K-Ras-driven tumors and their associated signaling pathways. Its specificity enables investigations into K-Ras's role in oncogenesis and therapy resistance.